Servier and Oncodesign, a French biopharmaceutical company dedicated to precision medicine, have been collaborating since last March on a strategic partnership for the research and development of one or more potential drug candidates for Parkinson’s disease.
Both companies today announce having reached ahead of schedule a first important milestone in the program, as LRRK2 inhibition has major potential in the treatment of Parkinson’s Disease
“The results were obtained sooner than expected which allowed us to reach our first Milestone several months in advance”, declares Philippe Genne, CEO and founder of Oncodesign. “We are very honored to collaborate successfully with Servier.”
[PR] @Oncodesign_SA & @Servier reach a key first milestone in their #strategic partnership on #LRRK2 inhibitors
They announce having reached a first important milestone in the program (#Parkinson‘s disease).
— Oncodesign (@Oncodesign_SA) February 17, 2020
This research and development partnership involves the LRRK2 kinase inhibitors and their potential to act as therapeutic agents against Parkinson’s disease. The partnership draws on the complementary expertise of Servier and Oncodesign in the field of neurodegenerative diseases and macrocyclic kinase inhibitors.
“We are very pleased with the rapid progress we have made together with Oncodesign in this collaborative program, with a very efficient and dynamic joint team, and look forward to continuing success over the coming years to reach our common goal of bringing a new treatment for patients who suffer from the scourge of Parkinson’s disease” declares Christophe Thurieau, Executive Director, Servier Research Institute,
Parkinson’s disease is a neurodegenerative disorder that affects approximately more than 6 million people worldwide.